Accelerate Diagnostics Inc. (AXDX) Stock Price Up 3.8%
Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares rose 3.8% during trading on Monday . The stock traded as high as $20.72 and last traded at $20.39, with a volume of 82,028 shares. The stock had previously closed at $19.65.
AXDX has been the subject of several analyst reports. Piper Jaffray Cos. restated a “buy” rating on shares of Accelerate Diagnostics in a research note on Monday, April 11th. BTIG Research restated a “buy” rating and issued a $26.00 target price on shares of Accelerate Diagnostics in a research note on Monday, April 11th. Finally, Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $22.67.
The firm’s market capitalization is $1.05 billion. The stock’s 50 day moving average price is $17.11 and its 200 day moving average price is $14.17.
In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 20,000 shares of the stock in a transaction dated Friday, May 13th. The shares were purchased at an average cost of $12.45 per share, with a total value of $249,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jack W. Schuler purchased 10,000 shares of the stock in a transaction dated Tuesday, May 17th. The shares were acquired at an average cost of $11.45 per share, for a total transaction of $114,500.00. The disclosure for this purchase can be found here.
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.